Sepsis Patients Display a Reduced Capacity to Activate Nuclear Factor-κB in Multiple Cell Types

被引:31
|
作者
Hoogendijk, Arie J. [1 ,2 ]
Garcia-Laorden, M. Isabel [1 ,2 ]
van Vught, Lonneke A. [1 ,2 ]
Wiewel, Maryse A. [1 ,2 ]
Belkasim-Bohoudi, Hakima [1 ,2 ]
Duitman, Jan Willem [1 ,2 ]
Horn, Janneke [3 ]
Schultz, Marcus J. [3 ,4 ]
Scicluna, Brendon P. [1 ,2 ]
Van tVeer, Cornelis [1 ,2 ]
de Vos, Alex F. [1 ,2 ]
van der Poll, Tom [1 ,2 ,5 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Amsterdam, Netherlands
[2] Ctr Infect & Immun Amsterdam, Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Lab Expt Intens Care & Anesthesiol, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Div Infect Dis, Amsterdam, Netherlands
关键词
immunosuppression; nuclear factor-kappa B; sepsis; signaling; whole blood stimulation; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE CK2; NEGATIVE REGULATION; MONONUCLEAR-CELLS; FACTOR-ALPHA; IMMUNOSUPPRESSION; PHOSPHORYLATION; PATHOPHYSIOLOGY; TRANSCRIPTION; INHIBITION;
D O I
10.1097/CCM.0000000000002294
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: Sepsis is a complex clinical condition associated with high morbidity and mortality. A distinctive feature of sepsis is the reduced capacity of leukocytes to release proinflammatory cytokines in response to ex vivo stimulation. Cellular signaling events leading to immunosuppression in sepsis are not well defined. We investigated cell-specific signaling events underlying the immuno-suppressed phenotype in sepsis. Design: Ex vivo study. Setting: ICU of an academic hospital. Patients: Nineteen patients with sepsis and 19 age-matched healthy controls. Interventions: None. Measurements and Main Results: The phosphorylation state of p38 mitogen activated protein kinase and nuclear factor kappa-light-chain-enhancer of activated B cells were determined in ex vivo stimulated CD4 T cells, CD8 T cells, B cells, monocytes, and neutrophils. Messenger RNA expression levels of p38 mitogen activated protein kinase and nuclear factor kappa-light-chain-enhancer of activated B cells and negative regulators tumor necrosis factor-alpha-induced protein 3 (A20) and mitogen activated protein kinase phosphatase-1 were determined in neutrophils and peripheral blood mononuclear cells. Upon ex vivo stimulation, monocytes of sepsis patients were less capable in phosphorylating nuclear factor kappa-light-chain-enhancer of activated B cells. Sepsis was also associated with reduced phosphorylation of nuclear factor kappa-light-chain-enhancer of activated B cells in stimulated B cells, CD4 and CD8 T cells. Messenger RNA expression levels of nuclear factor kappa-light-chain-enhancer of activated B cells and A20 were diminished in peripheral blood mononuclear cells of sepsis patients, whereas p38 mitogen activated protein kinase messenger RNA was up-regulated. In neutrophils of sepsis patients, mitogen activated protein kinase phosphatase-1 messenger RNA levels were down-regulated. Conclusions: Sepsis-induced immunosuppression associates with a defect in the capacity to phosphorylate nuclear factor kappa-light-chain-enhancer of activated B cells in lymphoid cells and monocytes.
引用
收藏
页码:E524 / E531
页数:8
相关论文
共 50 条
  • [21] The effects of genistein and puerarin on the activation of nuclear factor-κB and the production of tumor necrosis factor-α in asthma patients
    Liu, Xiao-Ju
    Zhao, Jin
    Gu, Xing-Yu
    PHARMAZIE, 2010, 65 (02): : 127 - 131
  • [22] New insights into the role of nuclear factor-κB in cell growth regulation
    Chen, F
    Castranova, V
    Shi, XL
    AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02): : 387 - 397
  • [23] A new look at T cell receptor signaling to nuclear factor-κB
    Paul, Suman
    Schaefer, Brian C.
    TRENDS IN IMMUNOLOGY, 2013, 34 (06) : 269 - 281
  • [24] RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma
    Roux, S
    Meignin, V
    Quillard, J
    Meduri, G
    Guiochon-Mantel, A
    Fermand, JP
    Milgrom, E
    Mariette, X
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) : 86 - 92
  • [25] Bortezomib-resistant nuclear Factor-κB activity in multiple myeloma cells
    Markovina, Stephanie
    Callander, Natalie S.
    O'Connor, Shelby L.
    Kirn, Jihoon
    Werndli, Jae E.
    Raschko, Martha
    Leith, Catherine P.
    Kahl, Brad S.
    Kim, KyungMann
    Miyamoto, Shigeki
    MOLECULAR CANCER RESEARCH, 2008, 6 (08) : 1356 - 1364
  • [26] Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
    Hideshima, Teru
    Ikeda, Hiroshi
    Chauhan, Dharminder
    Okawa, Yutaka
    Raje, Noopur
    Podar, Klaus
    Mitsiades, Constantine
    Munshi, Nikhil C.
    Richardson, Paul G.
    Carrasco, Ruben D.
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (05) : 1046 - 1052
  • [27] Biologic sequelae of nuclear factor-κB blockade in multiple myeloma:: therapeutic applications
    Mitsiades, N
    Mitsiades, CS
    Poulaki, V
    Chauhan, D
    Richardson, PG
    Hideshima, T
    Munshi, N
    Treon, SP
    Anderson, KC
    BLOOD, 2002, 99 (11) : 4079 - 4086
  • [28] The role of nuclear factor-κB essential modulator (NEMO) in B cell development and survival
    Kim, S
    La Motte-Mohs, RNA
    Rudolph, D
    Zúñiga-Pflücker, JC
    Mak, TW
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (03) : 1203 - 1208
  • [29] Sulfasalazine inhibits activation of nuclear factor-κB in patients with ulcerative colitis
    Gan, HT
    Chen, YQ
    Ouyang, Q
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (07) : 1016 - 1024
  • [30] Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver
    Boden, G
    She, PX
    Mozzoli, M
    Cheung, P
    Gumireddy, K
    Reddy, P
    Xiang, XQ
    Luo, ZJ
    Ruderman, N
    DIABETES, 2005, 54 (12) : 3458 - 3465